JP2004520041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520041A5 JP2004520041A5 JP2002558535A JP2002558535A JP2004520041A5 JP 2004520041 A5 JP2004520041 A5 JP 2004520041A5 JP 2002558535 A JP2002558535 A JP 2002558535A JP 2002558535 A JP2002558535 A JP 2002558535A JP 2004520041 A5 JP2004520041 A5 JP 2004520041A5
- Authority
- JP
- Japan
- Prior art keywords
- bace
- polypeptide
- nogo
- modulator
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 22
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 238000000034 method Methods 0.000 claims 15
- 102000010410 Nogo Proteins Human genes 0.000 claims 12
- 108010077641 Nogo Proteins Proteins 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0101312.7A GB0101312D0 (en) | 2001-01-18 | 2001-01-18 | Assay |
| PCT/GB2002/000228 WO2002057483A2 (en) | 2001-01-18 | 2002-01-18 | Method of identifying modulators of nogo-functions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004520041A JP2004520041A (ja) | 2004-07-08 |
| JP2004520041A5 true JP2004520041A5 (https=) | 2005-12-22 |
Family
ID=9907052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002558535A Pending JP2004520041A (ja) | 2001-01-18 | 2002-01-18 | 新規アッセイ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7270962B2 (https=) |
| EP (1) | EP1390758A2 (https=) |
| JP (1) | JP2004520041A (https=) |
| AU (1) | AU2002225174A1 (https=) |
| GB (1) | GB0101312D0 (https=) |
| WO (1) | WO2002057483A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130347A2 (en) * | 2010-04-13 | 2011-10-20 | The Johns Hopkins University | Methods for enhancing axonal regeneration |
| CN119768424A (zh) * | 2022-08-22 | 2025-04-04 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304224B6 (cs) * | 1998-11-06 | 2014-01-15 | Schwab | Monoklonální protilátka |
| US7087399B1 (en) * | 1999-05-13 | 2006-08-08 | Scios, Inc. | β-secretase and modulation of β-secretase activity |
| IL150566A0 (en) | 2000-01-12 | 2003-02-12 | Univ Yale | Nucleic acids and polypeptides and nogo-receptor proteins |
| GB0101313D0 (en) | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
-
2001
- 2001-01-18 GB GBGB0101312.7A patent/GB0101312D0/en not_active Ceased
-
2002
- 2002-01-18 US US10/466,258 patent/US7270962B2/en not_active Expired - Fee Related
- 2002-01-18 JP JP2002558535A patent/JP2004520041A/ja active Pending
- 2002-01-18 WO PCT/GB2002/000228 patent/WO2002057483A2/en not_active Ceased
- 2002-01-18 AU AU2002225174A patent/AU2002225174A1/en not_active Abandoned
- 2002-01-18 EP EP02715526A patent/EP1390758A2/en not_active Withdrawn
-
2007
- 2007-08-10 US US11/836,887 patent/US20070286851A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fan et al. | Research progress of vagus nerve stimulation in the treatment of epilepsy | |
| Carlson et al. | Conditional overexpression of insulin-like growth factor-1 enhances hippocampal neurogenesis and restores immature neuron dendritic processes after traumatic brain injury | |
| WO2008105797A3 (en) | Polynucleotides encoding novel pcsk9 variants | |
| BRPI0410296A (pt) | sistema e método para a determinação da eficácia de tratamento de distúrbios neurológicos utilizando o eletroencefalograma | |
| Shabir et al. | Assessment of neurovascular coupling and cortical spreading depression in mixed mouse models of atherosclerosis and Alzheimer’s disease | |
| Duricki et al. | Delayed intramuscular human neurotrophin-3 improves recovery in adult and elderly rats after stroke | |
| Tinazzi et al. | Deficits of temporal discrimination in dystonia are independent from the spatial distance between the loci of tactile stimulation | |
| NZ592516A (en) | Antibodies to il-6 and use thereof | |
| IS8432A (is) | Mótefni sem bindast viðtaka hvítfrumuboða-4 | |
| Lindemann et al. | Vagus nerve stimulation reduces spreading depolarization burden and cortical infarct volume in a rat model of stroke | |
| IL178121A0 (en) | Therapeutic use of anti-cs1 antibodies | |
| CR10627A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
| WO2008011083A3 (en) | Compounds for enhancing arginase activity and methods of use thereof | |
| RU2016151179A (ru) | Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента | |
| JP2004520041A5 (https=) | ||
| WO2006112951A3 (en) | Method of risk management for patients undergoing natalizumab treatment | |
| JP2009505979A5 (https=) | ||
| WO2004100886A3 (en) | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| JP2004531697A5 (https=) | ||
| Khetarpal et al. | Comparison of spinal anesthesia and paravertebral block in inguinal hernia repair | |
| JP2020007333A5 (https=) | ||
| ATE490979T1 (de) | Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene | |
| Mauguiere et al. | HM never again! An analysis of HM’s epilepsy and treatment | |
| EP1363528A4 (en) | METHODS OF DIAGNOSING AND TREATING CARDIOPATHIES |